Medical strategies to reduce amputation in patients with type 2 diabetes

Rayaz Malik, S. Tesfaye, D. Ziegler

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Lower extremity amputation is a common and disabling complication of Type 2 diabetes. Whilst the introduction of specialist multidisciplinary teams has led to a reduction in the incidence of lower extremity amputation in some centres, the overall prevalence of diabetes-related amputation has actually increased in recent decades. The aetiology of diabetes-related amputation is complex, with neuropathy, macrovascular and microvascular disease contributing significantly. Ulceration, previous amputation, increasing diabetes duration and poor long-term control of glycaemia and lipids are important risk factors for amputation in populations with diabetes. Major randomized intervention trials of blood glucose-lowering or anti-hypertensive therapies in populations with diabetes have shown limited reductions in neuropathy and/or macrovascular disease, and no benefit on amputation rates. In contrast, a recent analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed a significantly reduced rate of minor, but not major amputations in patients with Type 2 diabetes treated with fenofibrate. Mechanistic studies are clearly needed to understand the basis of this benefit.

Original languageEnglish
Pages (from-to)893-900
Number of pages8
JournalDiabetic Medicine
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2013
Externally publishedYes

Fingerprint

Amputation
Type 2 Diabetes Mellitus
Fenofibrate
Lower Extremity
Antihypertensive Agents
Population
Blood Glucose
Lipids
Incidence

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Medical strategies to reduce amputation in patients with type 2 diabetes. / Malik, Rayaz; Tesfaye, S.; Ziegler, D.

In: Diabetic Medicine, Vol. 30, No. 8, 08.2013, p. 893-900.

Research output: Contribution to journalReview article

Malik, Rayaz ; Tesfaye, S. ; Ziegler, D. / Medical strategies to reduce amputation in patients with type 2 diabetes. In: Diabetic Medicine. 2013 ; Vol. 30, No. 8. pp. 893-900.
@article{058742b27aaa4dea8696fa2a72b5df40,
title = "Medical strategies to reduce amputation in patients with type 2 diabetes",
abstract = "Lower extremity amputation is a common and disabling complication of Type 2 diabetes. Whilst the introduction of specialist multidisciplinary teams has led to a reduction in the incidence of lower extremity amputation in some centres, the overall prevalence of diabetes-related amputation has actually increased in recent decades. The aetiology of diabetes-related amputation is complex, with neuropathy, macrovascular and microvascular disease contributing significantly. Ulceration, previous amputation, increasing diabetes duration and poor long-term control of glycaemia and lipids are important risk factors for amputation in populations with diabetes. Major randomized intervention trials of blood glucose-lowering or anti-hypertensive therapies in populations with diabetes have shown limited reductions in neuropathy and/or macrovascular disease, and no benefit on amputation rates. In contrast, a recent analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed a significantly reduced rate of minor, but not major amputations in patients with Type 2 diabetes treated with fenofibrate. Mechanistic studies are clearly needed to understand the basis of this benefit.",
author = "Rayaz Malik and S. Tesfaye and D. Ziegler",
year = "2013",
month = "8",
doi = "10.1111/dme.12169",
language = "English",
volume = "30",
pages = "893--900",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Medical strategies to reduce amputation in patients with type 2 diabetes

AU - Malik, Rayaz

AU - Tesfaye, S.

AU - Ziegler, D.

PY - 2013/8

Y1 - 2013/8

N2 - Lower extremity amputation is a common and disabling complication of Type 2 diabetes. Whilst the introduction of specialist multidisciplinary teams has led to a reduction in the incidence of lower extremity amputation in some centres, the overall prevalence of diabetes-related amputation has actually increased in recent decades. The aetiology of diabetes-related amputation is complex, with neuropathy, macrovascular and microvascular disease contributing significantly. Ulceration, previous amputation, increasing diabetes duration and poor long-term control of glycaemia and lipids are important risk factors for amputation in populations with diabetes. Major randomized intervention trials of blood glucose-lowering or anti-hypertensive therapies in populations with diabetes have shown limited reductions in neuropathy and/or macrovascular disease, and no benefit on amputation rates. In contrast, a recent analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed a significantly reduced rate of minor, but not major amputations in patients with Type 2 diabetes treated with fenofibrate. Mechanistic studies are clearly needed to understand the basis of this benefit.

AB - Lower extremity amputation is a common and disabling complication of Type 2 diabetes. Whilst the introduction of specialist multidisciplinary teams has led to a reduction in the incidence of lower extremity amputation in some centres, the overall prevalence of diabetes-related amputation has actually increased in recent decades. The aetiology of diabetes-related amputation is complex, with neuropathy, macrovascular and microvascular disease contributing significantly. Ulceration, previous amputation, increasing diabetes duration and poor long-term control of glycaemia and lipids are important risk factors for amputation in populations with diabetes. Major randomized intervention trials of blood glucose-lowering or anti-hypertensive therapies in populations with diabetes have shown limited reductions in neuropathy and/or macrovascular disease, and no benefit on amputation rates. In contrast, a recent analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed a significantly reduced rate of minor, but not major amputations in patients with Type 2 diabetes treated with fenofibrate. Mechanistic studies are clearly needed to understand the basis of this benefit.

UR - http://www.scopus.com/inward/record.url?scp=84880687486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880687486&partnerID=8YFLogxK

U2 - 10.1111/dme.12169

DO - 10.1111/dme.12169

M3 - Review article

VL - 30

SP - 893

EP - 900

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 8

ER -